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Abstract 
Diquaternary ammonium gemini surfactants are a class of non-viral gene delivery vectors, 
primarily studied for their dermal applications. However, their biological fate has rarely been 
investigated. In this work, we developed simple flow injection analysis tandem mass spectrometric 
methods, (FIA)-MS/MS, to understand the fate and biodistribution of topically applied gemini 
surfactant-based therapeutics in an ex-vivo skin model.  
Three peptide-modified gemini surfactants with varied structures and transfection 
efficiencies were evaluated. For each compound, two methods were developed to quantify their 
presence in skin tissue and in phosphate buffered saline (PBS). The methods were developed using 
single-point calibration mode. Skin penetration was assessed on CD1 mice dorsal skin tissue 
mounted in a Franz diffusion cell after extraction. Amongst the five evaluated liquid-liquid 
extraction protocols, the Folch method provides the highest extraction efficiency for all 
compounds. Weak cationic exchange solid phase extraction was also used to further isolate gemini 
surfactants from endogenous skin lipids. FIA–MS/MS analysis of the skin revealed that all 
compounds were detected in the skin with minimal partition into the PBS compartment, which 
represents circulation. Interestingly, the detected amounts of gemini lipids in the skin were 
correlated with their transfection efficiencies.     
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Introduction  
Recent advances in discovering the genetic basis of many dermatological disorders have 
found cutaneous gene therapy to be a promising therapeutic option [1]. Cutaneous delivery of 
genetic material offers numerous advantages over other routes of administration, such as 
minimizing systematic toxicity, bypassing first-pass metabolism, and avoiding rapid clearance 
from the systemic circulation [2]. Despite these advantages, skin is a formidable barrier to foreign 
materials, such as nanotechnology products [3]. Therefore, effective delivery systems capable of 
penetrating the cutaneous barrier and facilitating recombinant DNA uptake into the skin are needed 
to achieve gene expression – the ultimate goal of gene therapy.  
Among topical delivery modalities currently being explored, lipid-based delivery vectors are 
at the forefront [4]. They have the ability to encapsulate, protect, and compact negatively charged 
nucleic acids, whereby forming nano-sized lipoplexes. Furthermore, the chemical composition of 
lipid-based nanocarriers bears some similarity to skin lipids, which enables them to fuse with the 
lipids in the stratum corneum, the outer layer of the skin; destabilizing the lipid matrix and 
enhancing drug penetration [5]. Diquaternary ammonium gemini surfactants are a class of lipid-
based delivery systems that are composed of dimeric surfactants with positively charged head 
groups and hydrocarbon tails linked by a spacer chain (Figure 1) [6]. The structure of gemini 
surfactants can be tailored to overcome skin barrier functions [7]. The topical application of gemini 
surfactant-based nanoparticles demonstrated a promising potential in the treatment of localized 
cutaneous scleroderma [7, 8]. Nanoparticles of N,N'-bis(dimethylhexadecyl)-1,3-
propanediammonium dibromide gemini surfactant complexed with pDNA encoding for interferon 
gamma (INF-γ) showed a significant increase in the level of INF-γ in mice [7, 8]. 
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Figure 1: Schematic representation of gemini surfactants showing the two ionic head groups, 
hydrocarbon tails and the spacer 
 
Despite advancements in the design of lipid-based nanocarriers, their biodistribution and 
biological fate have been less explored. Upon topical application, lipid-based nanoparticles 
distribute within various layers and cellular components. At present, the biodistribution, 
intracellular trafficking, and the ultimate fate of the lipid vector, after releasing its therapeutic 
cargo, are not fully understood. A fundamental understanding of the behavior of the lipid-based 
vectors in complex biological environments is essential in guiding the design of safer and more 
effective nanoparticles.  
To track the fate and distribution of lipid-based nanoparticles, fluorescently labeled and 
radiolabeled carriers are the most commonly used strategies. However, labeling techniques have 
drawbacks, particularly their tendency to alter the physicochemical properties of the delivery 
system. These modifications, in turn, change the pharmacokinetic profile of the nanocarriers [9]. 
Furthermore, they are unable to distinguish between the localization of a labeled molecule and the 
3 
 
metabolites that retain the fluorescent or radioactive probes [10]. Therefore, a more robust and 
sensitive analytical technique should be employed to identify and quantify gene-based carriers in 
complex biological samples. 
Mass spectrometry (MS) is an ideal technique to monitor the fate of gemini surfactants in 
the skin [11, 12]. It is a label-free technique with a powerful chemical identification capability and 
is gaining popularity in pharmaceutical sciences due to its high selectivity and sensitivity [13]. 
Coupling liquid chromatography to tandem mass spectrometry (LC–MS/MS) allows for reliable 
high throughput qualitative and quantitative analysis [14]. In fact, it is the gold standard technology 
for the quantification of pharmaceuticals in complex biological matrices [15]. 
In our laboratory, we developed two LC–MS/MS methods for the quantification of 
unsubstituted diquaternary ammoniums gemini surfactants (N, N-bis(dimethylalkyl)-α,ω-alkane-
diammonium), amine substituted diquaternary ammoniums compounds, and heterocyclic 
headgroup gemini surfactants (bis(alkyl-pyridinum) in epidermal keratinocytes [16, 17]. These 
methods provided essential information about the rate of cellular uptake and intracellular depletion 
of gemini surfactants [16, 17]. Currently, these methods are being employed to determine the 
subcellular localization of gemini surfactants and identify any potential metabolites. Recently, a 
new series of peptide modified diquaternary ammoniums gemini surfactants was found to exhibit 
superior transfection efficiency compared to previous generations of gemini surfactants [18]. Their 
collision-induced dissociation (CID)-MS/MS behaviour was evaluated, establishing a universal 
mass spectrometric fingerprint, essential for the development of targeted LC-MS qualitative and 
quantitative methods [11].  
Herein, we resolved a significant analytical challenge, the efficient extraction of gemini 
surfactants from lipid rich skin tissues. Efficient analytical platforms are needed to guide the 
development of effective pharmaceutical formulations. Three representative compounds were 
selected with high, low, and moderate transfection efficiencies. Subsequently, rapid and simple 
flow injection analysis (FIA)-MS/MS methods were developed to detect and quantify peptide-
modified gemini surfactants in skin tissues as well as in phosphate buffered saline (PBS).  
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Materials and methods  
Materials  
The evaluated peptide-modified gemini surfactants, designated as 16-7N(R)-16 where 16 
is the alkyl chain length and R is the peptide-containing moiety: R= glycyl-lysine, glycyl-hexyl-
trilysine and glycyl-undecyl-trilysine (Figure 2), were synthesized using previously reported 
synthetic methods [18]. The corresponding internal standards were synthesized using the same 
synthetic procedure with the incorporation of deuterated lysine moiety bearing four deuterium 
atoms (Figure S1, Supplementary Material). The plasmid pGThCMV.IFNGFP (pDNA), encoding 
for murine interferon gamma (IFN-γ) and green fluorescent protein (GFP) was utilized in this work 
[7].  
The helper lipid 1,2-dioleoyl-snglycerol-3-phosphoethanolamine (DOPE) was purchased 
from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Sucrose, used as a stabilizing agent, and 
phosphate buffered saline (PBS) were purchased from Sigma Aldrich (Oakville, ON, Canada). 
Mass spectrometry-grade methanol, water, and acetonitrile were purchased from Fisher Scientific 
(Nepean, ON, Canada). Formic acid (purity 90%) was obtained from EMD Chemicals Inc. (Merck 
KGaA, Darmstadt, Germany). Anhydrous chloroform and methyl tert-butyl ether (MTBE) used as 
extraction solvents were purchased from Sigma Aldrich (Oakville, ON, Canada). Solid phase 
extraction cartridges, Bond Elute® CBA, were obtained from Agilent Technologies (Mississauga, 
ON, Canada).  
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Figure 2: Chemical structure of gemini surfactants 16-7N(G-K)-16 (A), 16-7N(G-C6-K3)-16 (B) 
and 16-7N(G-C11-K3)-16 surfactants showing their precursor ion and the monitored product ions. 
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Preparation of topical formulations  
Cationic gemini lipids were combined with 16 µg pDNA at a negative to positive charge 
ratio (N/P) of 1:5 in the presence of a helper lipid DOPE to create pDNA/gemini lipid/helper lipid 
(P/G/L) nanoparticles. The concentration of the gemini surfactants was calculated so that the 
amount of gemini surfactants is enough to achieve the required charge ratio. As such, an 
appropriate amount of 30 mM aqueous solutions of gemini surfactant was added to 2 mg/mL 
pDNA solution and incubated for 20 minutes at room temperature (P/G complex). 2 mM DOPE 
was prepared as described previously [19] then concentrated to 10mM using Eppendorf 
concentrator 5301(Eppendorf, Hamburg, Germany). The concentrated DOPE was added to P/G 
complexes at a gemini surfactant to DOPE molar ratio of 1:16 to form the final nanoparticles 
(P/G/L) and incubated at room temperature for 20 minutes.  
Ex vivo skin penetration study 
Dorsal skin tissues were collected from female CD1 mice (Charles River Laboratories, 
Saint-Constant, QC, Canada) weighing around 22-24 g. Approval for this study was granted by 
the University of Saskatchewan’s Animal Research Ethics Board in adherence to the Canadian 
Council on Animal Care guidelines for humane animal use (protocol # 20090081). The animals 
were shaved and the skin was collected and stored at -80 °C until use.  
Skin penetration was evaluated using multi-station Franz diffusion cell system with 64 
mm2 surface area (PermeGear Inc., Hellertown, PA, USA). The skin tissue was mounted between 
the donor and receptor compartments of the Franz cell with the stratum corneum facing the donor 
compartment. The receiving chamber was filled with 5 mL PBS, avoiding any air bubbles between 
the skin and the solution. The skin tissues were allowed to equilibrate for 10 minutes before 
applying any formulation. A total 200 µL of peptide modified gemini surfactant-based lipoplexes 
containing 16 µg pDNA was placed in the donor compartment and the chamber was covered with 
parafilm. Throughout the experiment, the PBS in the receptor compartment was continuously 
stirred at 700 rpm using a magnetic stirrer bar and temperature was maintained at 32 °C using a 
circulating water bath (Fisher Scientific, Nepean, ON, Canada).  
Aliquots of 200 µL were withdrawn from the receptor compartment at fixed intervals (2, 
4, 6, 8, 12, 18 and 24 h) and replaced with an equal volume of pre-warmed PBS. After 24 hours, 
any remaining formulation in the donor chamber was aspirated and the skin tissue was removed 
from the Franz cell. The skin was rinsed thoroughly with water, blotted with tissue paper, then 
stripped 10 times with Scotch adhesive tape. The collected skin tissues and PBS samples were 
stored at -80 °C prior to analyte extraction and FIA-MS/MS analysis. 
Sample preparation for FIA-MS/MS analysis 
Skin tissue (40 mg) was spiked with 200 µL of methanol containing 0.03 mM of the 
corresponding internal standards for 16-7N(G-Kd4)-16 as well as 16-7N(G-C11-Kd4-K2)-16  and 
0.015 mM of 16-7N(G-C6-Kd4-K2)-16. After adding the extraction solvent, the skin was 
homogenized using a probe homogenizer (PRO200 Homogenizer, PRO Scientific Inc., Oxford, 
Connecticut, USA). During homogenization, the sample was kept on ice to avoid overheating. Five 
extraction solvent protocols were evaluated as explained below.   
Liquid-liquid extraction protocols 
Modified Folch method  
The analytes were extracted as described in the Folch protocol [20]  modifications by the 
addition of 200 µL methanol containing the internal standards, followed by the addition of 400 µL 
chloroform. Then, the skin sample was homogenized in the presence of ice to avoid overheating. 
High purity water (150 µL) was added to the homogenate to induce phase separation followed by 
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pulse vortexing for a few seconds. The sample was centrifuged at 14,000 rpm for 10 min at room 
temperature to obtain separate aqueous and organic phases. The bottom organic phase was 
retrieved while the upper aqueous phase and the skin pellet were re-extracted by the addition of 
400 µL chloroform as described above. The upper phase was discarded and both organic phases 
were combined, dried using a centrifugal evaporator, and stored at -80°C until analysis. 
Modified Bligh and Dyer method (B&D)  
The analytes were extracted by employing the Bligh and Dyer method with some 
modifications [21], by adding 80 µL high purity water, 200 µL methanol containing the internal 
standards and 100 µL chloroform to the skin tissue. Additional 100 µL chloroform was added, 
followed by 100 µL water while the sample was homogenized. Subsequently, the homogenate was 
centrifuged at 14,000 rpm for 10 min at room temperature. Similar to the modified Folch protocol, 
the lower organic layer was collected while the upper aqueous layer and the skin pellet were re-
extracted with additional 200 µL chloroform. Finally, the organic layers were combined, dried 
with a centrifugal evaporator, and stored at -80°C.  
Acidified/alkaline B&D method  
The analytes and internal standards were extracted as described in the Bligh and Dyer 
protocol, except that either 2 µL of 3M hydrochloric acid [22] or 0.3% 12 M ammonium hydroxide 
[23] was added to the pre-homogenization mixture.  
Modified methyl-tert-butyl ether (MTBE) method 
The analytes were extracted as described [24], with modifications, by adding 200 µL 
methanol containing the internal standards, then 666 µL MTBE. Subsequently, the tissue sample 
was homogenized in the presence of ice to avoid overheating. Afterwards, phase separation was 
induced by adding 166 µL water followed by pulse vortexing for a few seconds. The homogenates 
were centrifuged for 10 min at 14,000 rpm then the upper organic layer was retrieved while the 
lower aqueous layer and the skin pellet were re-extracted by adding 666 µL MTBE. After final 
centrifugation, both organic phases were combined and dried before being stored at -80°C. Figure 
3 summarizes the discussed liquid-liquid extraction protocols.  
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Figure 3: Flowchart summarizing the five evaluated liquid-liquid extraction methods.  
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Solid phase extraction (SPE) protocol  
Extracts from each solvent system were solubilized in 3 mL methanol-water (50:50, v/v). 
The CBA cartridges were activated by successive additions of 3 mL methanol, 3 mL water, and 
3mL methanol-water mixture (50:50, v/v). Subsequently, extracts were loaded into the cartridges 
followed by washing steps with 3 mL pure water and 3 mL methanol. Retained analytes and 
internal standards were eluted with 6 mL concentrated HCL-methanol (2:98, v/v). Finally, sample 
elutes were dried using a centrifugal evaporator and stored at -80°C.  
Prior to MS analysis, extracted analytes were reconstituted in 3 mL methanol with 0.1% 
formic acid. Same procedure was followed to extract the analytes of interest from the PBS used in 
Franz cell’s receptor compartment.   
FIA-MS/MS instrumentation 
FIA-MS/MS was performed on an Agilent 1290 infinity UHPLC (Agilent Technologies, 
Mississauga, ON, Canada) interfaced to an AB SCIEX QTRAP® 6500 triple quadrupole-linear 
ion trap mass spectrometer (QqLIT-MS) (AB SCIEX, Concord, ON, Canada). The mobile phase 
was optimized for each compound to achieve better ionization and peak shape. Isocratic mobile 
phase composed of acetonitrile/water mixture (50:50, v/v for 16-7N(G-K)-16 and 90:10, v/v for 
the rest of compounds) with 0.1% formic acid was delivered at a flow rate of 0.3 mL/min for a run 
time of 4 min. Sample aliquots of 1 µL were injected while maintaining the auto sampler 
temperature at 4 °C.  
The AB SCIEX QTRAP® 6500 is equipped with a “Turbo V Ion Spray” ESI source, 
operated in the positive ion mode and set at 5500 V ionspray voltage. Optimal detection parameters 
for each analyte are listed in Table 1. The MS/MS data were obtained by low energy collision-
induced dissociation (CID) employing nitrogen as the collision gas. Multiple reaction monitoring 
(MRM) was selected as the scan mode to monitor the analytes and internal standards precursor 
ions to product ions transitions. Dwell time for all transitions was 150 ms at unit resolution. The 
monitored transitions and their MRM conditions are listed in Table 2. The structures of the 
monitored transitions are shown in Figure 2 as well as Figure S1 (Supplementary Material).  
Table 1: Optimal detection parameters of the tested analytes on the AB SCIEX 6500 QTRAP® 
system.  
 
Gemini Surfactants Curtain gas, CUR (psi) 
Nebulizer gas, 
GS1 (psi) 
Heater gas, GS2 
(psi) 
Collision gas, 
CAD (psi) 
Source 
temperature 
(°C) 
16-7N(G-K)-16 45 50 80 10 700 
16-7N(G-C6-K3)-16 45 60 60 11 700 
16-7N(G-C11-K3)-16 45 70 90 10 600 
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Table 2: Conditions for MRM transitions of the gemini surfactants on AB SCIEX 6500 
QTRAP® System. 
 
Gemini surfactant Transition (m/z) DP (eV) CE (eV) CXE (eV) 
16-7N(G-K)-16 
411.4 → 276.9 151 27 10 
411.4→ 268.4 151 29 20 
16-7N(G-Kd4)-16 413.5 → 278.9 151 27 18 
16-7N(G-C6-K3)-16 
397.8 → 532.1 101 25 26 
397.8 → 268.2 101 33 10 
16-7N(G-C6-Kd4-K2)-16 399.2 → 534.2 101 23 26 
16-7N(G-C11-K3)-16 
421.2 → 338.3 141 35 18 
421.2 → 378.4 141 23 18 
16-7N(G-C11-Kd4-K2)-
16 422.5 → 379.8 116 23 18 
 
Preparation of standard solutions  
In this work, two methods were developed for each gemini surfactant: method A to 
determine their presence in the skin tissues and method B to monitor their cumulative amount 
permeated into the PBS solution.  
Method A: 
Aqueous stock solutions of gemini surfactants and their internal standards were prepared 
at a concentration of 3mM and stored at -20 °C. Working stock solutions were prepared daily by 
serial dilution of the stock solutions in methanol to concentrations of 0.03 mM and 0.015 mM. 
One point calibration standards were prepared by adding 400 µL of 0.03 mM target analyte and 
200 µL of 0.03 mM from the corresponding internal standards to 2.4 mL pooled blank skin tissue 
extract. The exception was with 16-7N(G-C6-K3)-16 gemini surfactants where 0.015 mM of the 
analyte and 0.015 mM IS were used, since the concentration of 16-7N(G-C6-K3)-16 in the skin 
was less than the other two compounds. The equivalent final mass concentration of the gemini 
surfactants and the corresponding internal standards are listed in Table S1, Supplementary 
Material.  
Method B: 
Aqueous stock solutions of gemini surfactants and their internal standards were prepared 
at a concentration of 3mM and stored at -20 °C. Working stock solutions were prepared daily by 
serial dilution of the stock solutions in methanol to concentrations of 3 µM and 1.5 µM. One point 
calibration standards were prepared by adding 60 µL of 3 µM target analyte (except for 16-7N(G-
C6-K3)-16 gemini surfactants where 1.5 µM was used) and 40 µL of 3 µM from the corresponding 
internal standards (except for 16-7N(G-C6-Kd4-K2)-16 where 1.5 µM was used) to 200 µL blank 
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PBS extract. The equivalent final mass concentration of the gemini surfactants and the 
corresponding internal standards are listed in Table S1, Supplementary Material.  
Method validation  
The methods were partially validated with respect to selectivity, recovery, matrix effect, 
and process efficiency as recommended by the USFDA guidelines [25]. The performance of the 
methods was evaluated by statistically comparing the slope of the three-point calibration curves 
for three intra-run measurements.  
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Data analysis 
Data processing for quantitative analysis was conducted using Analyst® software (Version 
1.6.0). A sample concentration was obtained according to single point calibration mode using the 
following equation.  
     (      )  =
                (      ) ×     (                    )
                (                    )    (1) 
The skin permeation parameters were calculated from the plot of cumulative amount of 
gemini surfactants permeated to the Franz diffusion cell’s receptor compartment divided by 0.64 
cm2 to correct for the exposed skin area as a function of time. Steady-state flux (Jss) was derived 
from the slope of the linear portion of the curve. The lag-time (tlag) was estimated from the intercept 
of the tangent to the linear part of the absorption profile on the time axis. The permeability 
coefficient Kp was calculated using the following equation [26]: 
   =             (2) 
where C dose is the concentration of the applied dose.  
Consequently, diffusion coefficient Dm and skin partition coefficient Km could be 
calculated as follows: 
   =     ×        (3) 
   =   ×        (4) 
where d is the measured skin thickness in cm.  
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Computational prediction 
The gemini surfactants partition coefficient (clog P), distribution coefficient (clog D) at 
varying pH, and aqueous solubility (clog S) were estimated using ACD/Physchem Profiler 2016 
[27] (Advanced Chemistry Development, Inc., Toronto, ON, Canada). 
Statistical analysis 
Statistical analyses were performed using SPSS software (Version 24.0). One way analysis 
of variance (ANOVA, Scheffé/Dunnett’s post hoc tests) and Pearson’s correlation were used for 
statistical analyses. Significant differences were considered at p<0.05 level.   
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Results and discussion  
Method development  
The major purpose of this work is to overcome an analytical challenge by developing 
simple and rapid MS-based methods for the detection and relative quantification of peptide-
modified gemini surfactants in skin tissues as well as in PBS. Analytical strategies should meet 
the need of the experiment; in our work, a fit-for-the-purpose approach was adopted as it provides 
the needed data to drive future formulation decisions. The developed methods aim to track the 
distribution of topically applied gemini surfactant-based therapeutics and investigate the impact of 
structural variation on the efficiency of skin penetration.  
LC-MS/MS is the most widely used platform for the quantification of pharmaceuticals in 
complex biological matrices, offering analyte separation and matrix effect reduction capabilities 
[15]. Despite these advantages, LC-MS/MS significantly increases the overall analysis time and 
associated costs [28]. The sensitivity and selectivity of modern MS instruments and the evolution 
of efficient sample preparation techniques allow the development of simple analytical procedures 
[29, 30]. Direct introduction of the sample into the MS using FIA (i.e. loop injection) has emerged 
as an effective approach that offers a rapid sample possessing rate, low cost, and method simplicity 
[31]. It has been successfully applied in the quantitation of several analytes, including 
pharmaceuticals, environmental contaminants, and endogenous compounds [32, 33]. Therefore, 
FIA-MS/MS methods were developed removing the need for chromatographic separation while 
relying on the MS separation capabilities. For each gemini surfactant, two methods were 
developed: method A to determine their presence in the skin and method B to monitor their 
cumulative amount permeated into the PBS. 
To ensure adequate selectivity and specificity of the developed method, we capitalized on 
the QTRAP capability in the MRM scan mode. The MS operational parameters such as 
declustering potential (DP), collision energy (CE), and collision exit potential (CXP) were 
optimized as shown in Table 2 to maintain ion abundance and stability. Two diagnostic MRM 
transitions with relatively high abundance, listed in Table 2, were selected for each compound. To 
improve accuracy and precision, an isotopically labelled internal standard bearing four deuterium 
atoms was used for each compound. The use of 4 mass unit difference between the analyte and its 
corresponding internal standard prevents any cross talk. The proposed structure of the monitored 
product ions for each gemini surfactant and their internal standards are shown in Figures 2 and S1 
(Supplementary Material), respectively.  
All tested compounds eluted before 0.8 min, as no column was used, with a total data 
acquisition time of 4 min (Figure 4A). No carryover was observed under the experimental 
conditions. This was significantly faster than the elution time in the recently developed HILIC-
based LC-MS/MS quantification method in which second generation amine substituted gemini 
surfactants eluted at 7.12 min [17]. It is noteworthy that peptide-modified gemini surfactants are 
more polar than amine substituted gemini surfactants, hence, longer elution times are expected for 
peptide-modified gemini surfactants if the HILIC-MS/MS method was applied.  
Selectivity 
Selectivity of the developed methods was assessed by monitoring the existence of 
interfering peaks of the evaluated analytes and their internal standards in murine skin tissue 
extracts as well as in PBS solution from 6 different sources (data not shown). As shown in Figure 
4 B and C, no interference from endogenous compounds against the selective bio-determination 
of the gemini surfactants was observed in both double blank skin tissue extracts and PBS. The 
ratio of the quantifier to the identifier transition ions were also monitored showing less than 9% 
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variations, indicating peak purity. The relative standard deviation (RSD) of the qualifier to the 
quantifier ratios was used as the acceptance criterion (less than 15%).  
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Figure 4: Representative FIA‐MS/MS chromatograms of (A) skin tissue extract of 16-7N(G-K)-
16 gemini surfactants, (B) double blank skin tissue extract, and (C) double blank PBS extract.  
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Sample preparation  
Sample preparation represents one of the most critical steps for obtaining reliable and 
sensitive quantitative data [34]. As such, the ability to extract gemini surfactants from skin tissues 
was thoroughly assessed in this work using five common liquid-liquid extraction protocols, namely 
Folch [20], B&D [21], Acidified B&D [22], Alkaline B&D [23], and MTBE [24]. Extraction of 
gemini surfactants from skin tissues posed an analytical challenge due to the complexity of the 
skin matrix and the presence of a wide variety of interfering substances such as proteins, salts, and 
lipids [35]. In fact, the main challenge was the lipid-rich nature of skin tissues that caused 
significant matrix effects (data not shown) due to the high affinity of the endogenous lipids to the 
organic phase, similar to the target analyte, i.e. the gemini surfactants. Therefore, further 
purification was necessary to isolate gemini surfactants from the skin’s endogenous lipids.  
Since the skin is composed of a wide variety of lipid classes ranging from highly non-polar 
to polar lipids [36]; we capitalized on the gemini surfactants’ unique feature, namely the two 
permanently charged quaternary amines to efficiently isolate them. Therefore, Bond Elute® CBA 
weak cationic exchange solid phase extraction (SPE) was used to purify extracts obtained from the 
liquid-liquid extractions. Bond Elute® CBA is a silica-based sorbent with a weak anion, carboxylic 
acid group, bonded to the surface. The carboxylic acid functional group has a pKa of 4.8 that is 
negatively charged at pH 6.8 and higher, allowing for strong ionic interaction with the positively 
charged nitrogen atoms of the gemini surfactants. Washing of the cartridges with non-acidic 
methanol and water was used to remove non-bonded skin lipids and other interfering substances. 
Finally, elution of the gemini surfactants was achieved by neutralizing the carboxylic acid 
functional group using acidified methanol (pH 2.8 and lower).  
Recovery, matrix effect, and process efficiency were evaluated across the five extraction 
protocol according to Matuszewski et al. [37] equations as follow:  
%          =
                                       
                                        
× 100    (5) 
%               =
                                      
                                   
 × 100    (6) 
%                    =  
                                      
                                   
× 100   (7) 
where the pre-extraction spiked sample refers to gemini surfactant standards added to the skin 
tissue before extraction and where samples were processed according to each liquid-liquid 
extraction procedure followed by purification with SPE. Response from the post-extraction spiked 
sample contains gemini surfactant standards added to the extracted blank tissues after passing 
through the SPE. The non-extracted neat sample contains the gemini surfactants added to the final 
reconstitution solvent (methanol with 0.1% formic acid). The determined value is the average for 
a set of triplicates. 
Table 3 displays the effect of the extraction protocols on the recovery, matrix effect, and 
process efficiency. The Folch method resulted in the highest extraction efficiency in all gemini 
surfactants while MTBE displayed the lowest efficiency. The higher extraction efficiency of Folch 
compared to B&D methods was in agreement with the notion that the Folch protocol is more suited 
for extracting lipids from tissues, whereas B&D is more successful for biological fluids [38]. 
Although both Folch and B&D methods are based on the biphasic chloroform-methanol-water 
mixtures, the Folch method uses a higher percentage of chloroform over methanol (Folch 
maintains the chloroform-methanol-water mixture at 8:4:3 while the B&D ratio is 2:2:1.8) [20], 
[21]. Chloroform is a widely used extraction reagent for analytes with intermediate polarity such 
as gemini surfactants, while methanol is not an ideal extraction solvent since it is miscible with 
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water. In fact, methanol is incorporated into the extraction mixture to disturb the interaction of the 
target analyte with the cellular biopolymers such as proteins, owing to its polarity and high 
dielectric constant [38]. Although methanol has recently been used as a monophasic extraction 
system for phospholipids in blood and polar lipids in the upper layer of human skin [39], in our 
experiments, it showed no success in extracting gemini surfactants from the skin tissues (data not 
shown).  
Adjustment of the pH in the B&D method is viewed as an effective way to optimize the 
extraction efficiency of specific classes of lipids [22, 23]. In the case of gemini surfactants, higher 
recovery and less ion suppression were reported with alkaline B&D compared to conventional 
B&D, however the differences were not statistically significant (Table 3). Alkaline medium caused 
an increase in logD values and a decrease in logS values of the tested gemini surfactants (Table 
4), resulting in their higher partition into the organic layer. In addition, the alkaline medium 
increases the polarity of the phosphate moiety of the skin natural lipids, which might increase their 
partition into the aqueous layer, minimizing interference with gemini surfactants.  
Acidified B&D was the least effective method among the B&D methods; it exhibited the 
highest ion suppression. This could be attributed to the higher affinity of the endogenous lipids to 
the organic phase under acidic conditions resulting in significant ion suppression. The addition of 
HCl neutralizes the negatively charged skin lipids resulting in increased hydrophobicity, hence, 
higher unfavorable partition into the organic phase.  
Extraction with MTBE was significantly the least effective among the evaluated extraction 
protocols (Table 3). This could be attributed to the lower polarity index of MTBE of 2.5 compared 
to chloroform of 4.1. MTBE was introduced as an alternative solvent system to chloroform that 
offered simplified sample handling [24]. It has a lower density than water and methanol, thus, it 
forms the upper layer during the extraction allowing for easier analyte collection. While it was 
suggested that extraction with MTBE is effective for most major classes of lipids, including polar 
and neutral lipids [24], contradictory reports indicate that MBTE was only able to extract 10% of 
major polar lipids [40].  
Comparison of the extraction efficiency among the three gemini surfactants revealed that 
16-7N(G-C11-K3)-16 exhibited the highest recovery in all extraction methods, followed by 16-
7N(G-K)-16, then 16-7N(G-C6-K3)-16 (Table 3). This trend was in accordance with the clog P 
values of the gemini surfactants in which the higher the compound hydrophobicity, the higher its 
affinity into the organic phase, hence the higher the extraction efficiency (Table 4). However, 
while there is a major difference in the clog P values between compound 16-7N(G-C11-K3)-16 and 
16-7N(G-K)-16 (3.27 and 2.8 respectively), the differences in the extraction efficiency is not as 
dramatic. This could be explained by the higher number of terminal lysine moieties in compound 
16-7N(G-C11-K3)-16 compared to 16-7N(G-K)-16 which exhibit higher affinity to bind to the 
negatively charged constituents of the skin. In fact, such speculation could explain the substantially 
low extraction efficiency of compound 16-7N(G-C6-K3)-16, which has three polar lysine residues 
and shorter hydrophobic spacer, conferring low lipophilicity to the molecule.  
Since the modified Folch method demonstrated the highest process efficiency, it was 
selected as the liquid-liquid extraction method for the bioanalysis. 
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Table 3: Recovery, matrix effect, and process efficiency of the evaluated-peptide modified gemini surfactants using different liquid-1 
liquid extraction protocol.  2 
 3 
 
Gemini surfactants 
 16-7N(G-K)-16 16-7N(G-C6-K3)-16 16-7N(G-C11-K3)-16 
Extraction Method % Recovery %Matrix effects 
%Process 
efficiency % Recovery 
%Matrix 
effects 
%Process 
efficiency % Recovery 
%Matrix 
effects 
%Process 
efficiency 
MTBE 51.80 ± 2 89.75± 6 56.67 ± 1 21.9 ± 3 75.29 ± 7 23.1 ± 5 53.98 ± 1 83.66±4 45.86 ± 0.8 
Folch 85.32 ± 7 71.48 ±6 75.06 ± 5 46.04 ± 7 71.8 ± 1 38.28 ± 0.3 93.82 ± 5 74.63 ±5 77.09 ± 3 
Blight&Dyer 74.18 ± 3 77.92± 4 69.01 ± 0.5 30.7 ± 1 53.44 ± 3 30.1 ± 0.8 76.57 ± 0.8 62.71± 2 60.88  ± 4 
Acidify B&D 60.17 ± 3 67.7 ± 6 60.81 ±5 28.37 ± 2 46.09 ± 0.9 29.64 ± 1 63.65 ± 5 53.91 ± 8 55.97 ± 4 
Alkaline  B&D 77.60 ± 2 88 ± 1 73.18 ± 2 39.9 ± 1 68.49 ± 4 31.2 ± 1 80.7 ± 6 67.24 ± 4 60.77 ± 0.5 
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 4 
Table 4: Physicochemical properties of the evaluated gemini surfactants estimated using 5 
ACD/Physchem Profiler.  6 
  7 
 Gemini surfactants 
Physicochemical 
properties 16-7N(G-K)-16 16-7N(G-C6-K3)-16 16-7N(G-C11-K3)-16 
clog P 2.80 1.28 3.27 
clog D at pH= 4 0.8 -2.7 -0.7 
clog D at pH= 6 1.0 -2.6 -0.6 
clog D at pH= 10 2.3 0.3 2.3 
clog S at pH= 4 -9.2 -7.6 -9.1 
clog S at pH= 6 -9.4 -7.7 -9.2 
clog S at pH= 10 -10.7 -10.6 -12.1 
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Single point calibration 8 
Fully validated quantification methods are usually needed for preclinical and clinical 9 
analysis, however, they require considerable time, workload, and resources [41]. In the case where 10 
full validation is not required, a “fit-for-the-purpose” approach is a more suited analytical strategy 11 
to obtain the needed data and is frequently used to answer predefined research questions [41, 42]. 12 
One common quantification strategy is single-point calibration; considered a compromise between 13 
the rigor of the analytical method and the workload without sacrificing the accuracy of the results. 14 
In fact, several studies compared single point to conventional multi-point calibration showing the 15 
usefulness of single-point calibration in providing quantitative data with accuracy and precision 16 
that meet regulatory guidelines [43, 44]. Since the scope of this work is to conduct a relative 17 
comparison among three gemini surfactants with varying transfection efficiencies; a one-point 18 
calibration quantitative strategy is deemed adequate to provide relative quantification data with 19 
acceptable accuracy and precision, effectively reducing the required time, resources, and cost of 20 
analysis.  21 
In single point calibration, one reference concentration is employed for the quantification 22 
of the analyte of interest. However, two conditions must be fulfilled: (i) the concentration-response 23 
function is linear and (ii) the y-intercept is negligibly small [45]. In this work, a single 24 
concentration of gemini surfactants was selected to serve as a calibration standard for each method: 25 
method A and method B (Table S1, Supplementary Material). The calibration standard was 26 
prepared in triplicate and the average response was used for quantification. The RSD values (i.e. 27 
precision) in all cases did not exceed 11%. The concentrations of selected calibration standards 28 
were relatively close to the concentration of the analytes in the skin tissue samples for method A 29 
and in the mid-range of the sample concentrations in the PBS solution (Table S1, Supplementary 30 
Material). The selection of each point was extrapolated from previous knowledge about the 31 
penetration behaviour of similar delivery vectors, which was then adjusted experimentally to best 32 
suit the method. Although some studies suggest that the linearity condition for single point 33 
calibration can be avoided if the analyte amount in the evaluated samples is close to its amount in 34 
the calibration standard, the linearity over the samples’ concentrations range was verified by 35 
developing a three-point calibration curve in the range of 1 µg/mL to 7 µg/mL for method A and 36 
of 50 ng/mL to 3000 ng/mL for method B. In order to assess the reliability and reproducibility of 37 
the methods, the slope of the three-point calibration curve for each method was statistically 38 
compared across at least three intra-run measurements. One way analysis of variance comparison 39 
suggested that the variations between the evaluated slopes were not significantly different 40 
(p<0.05), indicating the reproducibility and reliability of the generated quantitative data.  41 
Skin penetration study  42 
The developed methods were used to assess the cutaneous deposition and penetration 43 
behaviour of the three peptide-modified gemini surfactants after the topical application of P/G/L 44 
nanoparticles. The selection of gemini surfactants was based on: (i) the variation in their molecular 45 
structure and (ii) their differences in transfection efficiency profiles. Namely, 16-7N(G-K)-16 was 46 
the lead compound with the highest transfection efficiency showing protein expression of 2.82 47 
±0.2 ng/ 15*103 in PAM 212 murine keratinocytes. On the other hand, 16-7N(G-C11-K3)-16 48 
demonstrated moderate transfection efficacy with protein expression of 1.73 ±0.2, while 16-7N(G-49 
C6-K3)-16 had a low transfection ability of 1.09 ±0.1. The choice of the three compounds was 50 
based on a comprehensive evaluation of over 20 compounds (data not shown, manuscript in 51 
preparation). Table 5 displays the skin disposition and penetration parameters of the gemini 52 
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surfactants obtained in accordance with the Organisation for Economic Co-operation and 53 
Development (OECD) guideline for determining the dermal penetration of chemicals [26]. 54 
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Table 5: Skin disposition and penetration parameters of the evaluated peptide-modified gemini surfactants. Results are the average of 55 
five measurements. Abbreviations: Jss: the steady-state flux, tlag: the lag-time, Kp: the skin permeability coefficient, Dm: diffusion 56 
coefficient and Km: partition coefficient. 57 
 Skin tissues Skin penetration parameter (receptor compartment) 
Gemini Surfactants 
Applied 
dose 
(µg/cm2) 
Amount in 
skin (µg/cm2) ± RSD (%) % Deposited in skin  
Total amount 
penetrated 
across skin 
(µg/cm2) ± 
RSD (%) 
% Penetrated  
across skin 
Jss 
(ng/cm2/h)  
t lag 
(h) 
Kp 
(cm/h) 
Dm 
(cm2/h) Km 
16-7N(G-K)-16 181.36 
 
20.30± 4 11.19 0.99± 0.01 0.55 50.59 5.0 2.79×10-4 2.70×10-4 0.93 
 
16-7N(G-C6-K3)-16 264.31 
 
10.45± 3 3.95 0.28±0.02  0.11 13.67 5.5 0.52×10-4 2.45×10-4 0.19 
16-7N(G-C11-K3)-16 277.46 
 
22.25 ± 5 8.02 0.86± 0.02 0.31 43.48 5.3 1.57×10-4 2.55×10-4 0.55 
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 58 
After 24 h of topical application, FIA–MS/MS analysis of the skin tissues revealed that 59 
3.95-11.19% of the applied dose of the three evaluated gemini surfactants was retained in the skin 60 
(Table 5). It is noteworthy that the detected amounts of gemini surfactants in the skin correlated 61 
with their transfection efficiency, where the lead compound 16-7N(G-K)-16 exhibited the highest 62 
skin deposition (11.19%) followed by 16-7N(G-C11-K3)-16 (8.02%) and the least performing 63 
compound 16-7N(G-K)-16 (3.95%). This could be explained by the gemini surfactants’ 64 
physicochemical properties, particularly lipophilicity and molecular size. In fact, it has been 65 
established in the literature that molecular size and hydrophobicity are the main determinants of 66 
dermal penetration suggesting that small hydrophobic compounds have a higher tendency to pass 67 
through the different layers of the skin [46]. In the evaluated model compounds, the lead 68 
compound, 16-7N(G-K)-16, with the highest skin deposition had the smallest molecular size 69 
(M.Wt. 967.24 g/mol) among the tested compounds; in addition, it showed the highest lipophilicity 70 
(clog D= 1.0) at the intrinsic pH of the formulation (pH=6, Table 4). However, while compound 71 
16-7N(G-C6-K3)-16 has a smaller molecular size than 16-7N(G-C11-K3)-16, it exhibited 72 
significantly less residence in the skin tissues (Table 5). This could be attributed to the significantly 73 
lower clog D value of the former (-2.7) compared to the latter (-0.6) at the formulation intrinsic pH 74 
of 6 (Table 4). This is in agreement with the reported trend in the literature where lower skin 75 
penetration is expected for compounds with higher molecular weight unless they have higher 76 
lipophilicity [47]. 77 
In addition to the lipophilicity and molecular size, several other parameters such as 78 
solubility might play a role in determining skin penetration ability. In the evaluated model 79 
compounds, skin penetration correlated negatively with the compounds’ aqueous solubility (clog 80 
S at pH 6, Table 4). Lower aqueous solubility is usually associated with a higher ability to penetrate 81 
through the lipid-rich stratum corneum [48].  82 
Finally, the physicochemical parameters of the P/G/L nanoparticles could also affect the 83 
dermal delivery. For example, small particle size and lower surface charge usually translate into 84 
higher skin penetration due to their superior ability to move through the complex skin matrix [49, 85 
50]. Evaluation of the size and zeta potential of the P/G/L nanoparticles revealed that the lead 86 
compound, 16-7N(G-K)-16, exhibited the smallest particle size (85 ± 2 nm) and lowest zeta 87 
potential (34 ± 2 mV) among the tested compounds. On the other hand, compound 16-7N(G-C11-88 
K3)-16 had a particle size of 96 ± 1 nm and a zeta potential of 44± 1 mV while 16-7N(G-C6-K3)-89 
16 with the least skin disposition demonstrated the largest particle size and zeta potential, i.e., 107 90 
± 3 nm and 52 mV, respectively.  91 
The cumulative amount of gemini surfactants that permeated across the skin into the 92 
receptor compartment increased progressively with time (Figure 5). After 24 h, only 0.11- 0.55% 93 
of the applied dose was found in the Franz cell diffusion receptor compartment. This is an 94 
indication that the gemini surfactant-based gene delivery system could be suitable for the treatment 95 
of localized skin conditions like scleroderma or melanoma with minimum passing into the 96 
systematic circulation.  97 
 98 
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Figure 5: Cumulative amount of gemini surfactants (ng/cm2) penetrated across the skin into the 99 
Franz cell diffusion receptor compartment versus time curves. Results are the average of five 100 
measurements, error bars represent standard deviation. 101 
 102 
From the linear part of the curves plotted in Figure 5, the steady-state flux (Jss), the lag-103 
time (tlag), the skin permeability coefficient (Kp), diffusion coefficient (Dm), and partition 104 
coefficient (Km) were calculated (Table 5). The time required before the steady state absorption 105 
occurs denoted as tlag was around 5 - 5.5 h for all compounds. The compound with the highest skin 106 
penetration 16-7N(G-K)-16 demonstrated the shortest tlag of 5.0 h, followed by 16-7N(G-C11-K3)-107 
16 (tlag =5.3 h), and 16-7N(G-C6-K3)-16, with tlag= 5.5 h (Table 5). Lag time is a reflection of the 108 
efficiency of the compound to pass through the different layers of the skin. Therefore, it is mainly 109 
influenced by the same parameters that determine skin permeability, namely lipophilicity, 110 
solubility, and molecular size [51]. While tlag inversely correlated with the clog D values at the 111 
formulation intrinsic pH, it directly correlated with clog S values (Table 4). The gemini surfactants’ 112 
net rate of transport, once equilibrium conditions have been reached, is described by the steady-113 
state flux (Jss). Similar to tlag, Jss is a representation of the efficiency of the compounds to penetrate 114 
the skin. As such, Jss is directly related to the total amount of gemini surfactants found in the Franz 115 
cell receptor compartment (Table 5).  116 
The permeability coefficient (Kp), which depicts the rate at which gemini surfactants 117 
penetrate the skin, diffusion coefficient (Dm), and partition coefficient (Km), are extracted from tlag 118 
and Jss (equations 2-4), thereby showing a direct relationship with the compounds’ hydrophobicity 119 
at the intrinsic pH, lipid solubility, and skin penetration ability (Table 4 and 5). Reporting these 120 
parameters is not only valuable for drug delivery but it is also of significant interest for assessing 121 
the toxicity and occupational risk of the gemini surfactants. 122 
Conclusion 123 
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In this work, rapid and simple FIA‐MS/MS methods were developed for the relative 124 
quantification of three peptide-modified gemini surfactants in skin tissues as well as PBS solution. 125 
Combining the Folch liquid-liquid extraction protocol with weak cationic exchange SPE enhanced 126 
the extraction efficiency of gemini surfactants from the complex lipid-rich skin tissues. As such, 127 
proper sample preparation (i.e., clean extracts) eliminated the need for HPLC column, resulting in 128 
fast analysis in which all compounds eluted before 0.8 min with a total acquisition time of merely 129 
4 min. In addition, single-point calibration was successfully employed, resulting in a significant 130 
reduction in the required time and resources for method development and sample analysis.  131 
The developed methods were applied to assess the skin deposition and skin penetration 132 
behavior of the evaluated gemini surfactants, generating data that could help in the design of more 133 
effective cutaneous lipid-based gene delivery vectors. The skin disposition and penetration 134 
behavior of gemini surfactants heavily relied on their physicochemical properties, particularly their 135 
lipophilicity. Furthermore, it correlated with the transfection efficiency of the gemini surfactants. 136 
A favorable deposition in the skin with minimum escape into the PBS compartment (representing 137 
circulation) was observed, suggesting the feasibility of the delivery system in a topical application. 138 
The developed methods will be further utilized to probe the biodistribution and fate of topically 139 
applied therapeutic gemini surfactant formulations in animal models. Such knowledge is 140 
fundamental before any translation from laboratory to clinical evaluation.  141 
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